hormonePrescription only (US)
EstradiolBenefits, Dosage & Interactions
Also known as: E2, Estrace
Estradiol (E2) is the most potent and abundant naturally occurring estrogen in the human body. It is a steroid hormone primarily responsible for the development and regulation of the female reproductive system and secondary sexual characteristics. Research on Estradiol focuses on bone and joint health, menopause symptoms, and women's healthspan.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 2 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
2 human randomized trials and regulatory approval on file.
Plasma half-life
~15 h
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for Estradiol in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Estradiol entry is written from. Each number matches an inline marker above.
- [1]Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trialsManson JE, Chlebowski RT, Stefanick ML, et al. · JAMA · 2013 · Peer-reviewed · PMID 24084921
- [2]Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective StudyGleason CE, Dowling NM, Wharton W, et al. · PLoS Medicine · 2015 · Peer-reviewed · PMID 26035291
How to track Estradiol doses
Estradiol is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so Estradiol is stored as a concentration rather than a guess. DoseRoutine converts that into mg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mg and the frequency. Cycled protocols get a start and end date so the history stays accurate when Estradiol comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 15 h, effects and timing shifts show up over days rather than instantly. Review Estradiol alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
References & Evidence
Sources on this page that document Estradiol dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Estradiol studied for?
What is Estradiol?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Estradiol (E2) is the most potent and abundant naturally occurring estrogen in the human body. It is a steroid hormone primarily responsible for the development and regulation of the female reproductive system and secondary sexual characteristics. Beyond reproduction, estradiol also plays crucial roles in bone health, cardiovascular function, cognitive function, and skin health. It is available in various pharmaceutical formulations, including oral tablets, transdermal patches, gels, sprays, and vaginal rings, to address different medical needs.
Endogenous estradiol is mainly produced by the ovaries in premenopausal women. Smaller amounts are also produced by the adrenal glands, fat tissue, and, in males, by the testes. Its production fluctuates throughout the menstrual cycle, peaking just before ovulation. After menopause, ovarian production significantly declines, leading to a state of estrogen deficiency that contributes to various menopausal symptoms and long-term health concerns.
In therapeutic contexts, estradiol is used as hormone replacement therapy (HRT) or menopausal hormone therapy (MHT) to alleviate menopausal symptoms such as hot flashes, night sweats, vaginal dryness, and mood swings. It is also prescribed for the prevention of postmenopausal osteoporosis, the treatment of hypogonadism (deficient gonadal function) in women, and sometimes in gender-affirming hormone therapy for transgender women. The specific formulation, dosage, and duration of estradiol treatment are individualized, often depending on the patient's symptoms, medical history, and risk factors.
What does the research say about Estradiol?
Tap a section to expand.
Estradiol exerts its effects primarily by binding to and activating estrogen receptors (ERs), specifically estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), which are ligand-activated transcription factors. These receptors are located in the cytoplasm and nucleus of target cells throughout the body. Upon estradiol binding, the receptor undergoes a conformational change, dimerizes, and translocates to the nucleus. In the nucleus, the estradiol-receptor complex binds to specific DNA sequences called estrogen response elements (EREs) in the promoter regions of target genes. This binding modulates gene transcription, leading to either an increase or decrease in the production of specific proteins that mediate estradiol's diverse physiological effects.
Beyond genomic effects, estradiol can also exert rapid, non-genomic effects through membrane-bound estrogen receptors or by interacting with other signaling pathways. These effects often involve second messenger systems and can occur within seconds to minutes, influencing processes such as vasodilation, neuronal excitability, and immune responses.
The specific effects of estradiol depend on the tissue in which the estrogen receptors are expressed and the specific type of receptor (ERα or ERβ) that is activated. For instance, ERα is highly expressed in the uterus, mammary glands, and hypothalamus, mediating reproductive and growth-promoting effects, while ERβ is more abundant in the ovaries, brain, bone, and immune system, often modulating tissue differentiation and a more protective role. Synthetic and bioidentical estradiol used in pharmaceuticals mimics the action of endogenous estradiol, binding to these same receptors to produce therapeutic effects.
Source for this section: Sources for How does Estradiol work?: Jumps to this entry in the sources and references list at the end of the page.
Estradiol offers a range of therapeutic benefits, primarily stemming from its role as the most potent naturally occurring estrogen. Its main clinical applications include:
* **Relief of Menopausal Symptoms:** Estradiol is highly effective in alleviating vasomotor symptoms (hot flashes and night sweats), vulvovaginal atrophy (vaginal dryness, itching, and irritation), and related urinary symptoms often experienced during menopause. It can also improve sleep disturbances and mood changes associated with hormone fluctuations (Mayo Clinic).
* **Prevention of Postmenopausal Osteoporosis:** Long-term use of estradiol, particularly when initiated early in menopause, can significantly reduce bone loss and decrease the risk of osteoporotic fractures in women (NIH ODS).
* **Treatment of Female Hypogonadism:** For women with deficient ovarian function due to various conditions (e.g., primary ovarian insufficiency, Turner syndrome, surgical removal of ovaries), estradiol therapy is essential for promoting the development of secondary sexual characteristics, establishing menstrual cycles, and maintaining bone health.
* **Gender-Affirming Hormone Therapy:** In transgender women, estradiol is a cornerstone of feminizing hormone therapy, promoting breast development, redistribution of body fat, reduction in body hair, and other feminizing changes (MedlinePlus).
* **Vaginal Dryness and Dyspareunia:** Localized vaginal estradiol formulations are highly effective in treating vaginal atrophy and dyspareunia (painful intercourse) without significant systemic absorption, making them a safer option for women where systemic HRT is contraindicated (NIH ODS).
These benefits are achieved by restoring estrogen levels to a more physiological range, thereby mitigating the symptoms and health risks associated with estrogen deficiency.
The therapeutic benefits and risks of estradiol have been extensively studied through numerous clinical trials and observational studies. Key findings and sources include:
* **Women's Health Initiative (WHI) Studies:** These large-scale clinical trials conducted by the National Institutes of Health provided significant data on the impact of various hormone therapies, including estradiol. They established the efficacy of estrogen in treating menopausal symptoms and preventing osteoporosis, while also identifying potential risks such as increased risk of blood clots, stroke, and certain cancers with combined estrogen-progestin therapy (NIH ODS).
* **Cochrane Reviews:** Numerous Cochrane reviews systematically analyze existing evidence on hormone therapy for menopausal symptoms and primary ovarian insufficiency, consistently concluding that estrogen therapy is effective for symptom relief and bone density maintenance (Cochrane).
* **FDA Label Information:** The FDA-approved product labels for various estradiol formulations provide detailed efficacy data, indications, contraindications, and warnings based on clinical trial results submitted for drug approval (FDA label).
* **Professional Medical Guidelines:** Organizations such as the American College of Obstetricians and Gynecologists (ACOG) and the North American Menopause Society (NAMS) publish evidence-based guidelines for the appropriate use of estradiol and other hormone therapies, drawing on comprehensive reviews of available research.
As with any medication, estradiol can cause side effects. These can vary depending on the dosage, formulation, and individual patient responses. Common side effects include:
* **Breast tenderness or pain:** This is a very common side effect, especially at the start of therapy.
* **Nausea:** Some individuals may experience nausea, particularly with oral formulations.
* **Headache:** Mild headaches are reported by some users.
* **Bloating:** Fluid retention leading to a sensation of bloating.
* **Mood changes:** Including irritability or depression.
* **Vaginal bleeding or spotting:** This can occur, especially if progestin is not also taken (in women with a uterus).
* **Weight changes:** Some individuals report weight gain or loss, though it's often multifactorial.
* **Skin irritation:** With transdermal patches or gels, local skin reactions at the application site.
More serious, though less common, side effects and risks associated with systemic estradiol therapy, particularly when combined with a progestin, include:
* **Blood clots (deep vein thrombosis and pulmonary embolism):** The risk is generally higher with oral formulations.
* **Stroke and heart attack:** Increased risk, particularly in older women or those with pre-existing cardiovascular risk factors.
* **Gallbladder disease:** Increased risk of gallstones.
* **Endometrial cancer:** If estradiol is used without a progestin in women with an intact uterus, it significantly increases the risk of endometrial hyperplasia and cancer. Progestin is given concurrently to mitigate this risk.
* **Breast cancer:** Some studies, especially the Women's Health Initiative, indicated an increased risk of breast cancer with long-term use of combined estrogen-progestin therapy (NIH ODS).
It is crucial to discuss any side effects with a healthcare provider. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Several important warnings are associated with estradiol therapy, necessitating careful evaluation and monitoring by a healthcare provider:
* **Cardiovascular Disorders:** An increased risk of stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE) has been observed, particularly with oral estrogen therapy. The risk of myocardial infarction (heart attack) has also been reported. Estradiol should be used with caution in individuals with established cardiovascular disease or multiple risk factors.
* **Malignant Neoplasms:** The use of unopposed estrogen (estrogen without a progestin) in women with an intact uterus is associated with an increased risk of endometrial cancer. A progestin should be co-administered in these cases. The Women's Health Initiative (WHI) study also suggested an increased risk of invasive breast cancer with combined estrogen and progestin therapy (NIH ODS, FDA label).
* **Dementia:** The WHI Memory Study (WHIMS) indicated an increased risk of probable dementia in postmenopausal women 65 years of age or older treated with combined estrogen and progestin therapy or estrogen-alone therapy (NIH ODS).
* **Gallbladder Disease:** Estrogens can increase the risk of gallbladder disease requiring surgery.
* **Hypercalcemia:** Estrogen administration may lead to severe hypercalcemia in patients with breast cancer and bone metastases.
* **Visual Abnormalities:** Retinal vascular thrombosis has been reported, which may result in partial or complete loss of vision. Discontinue estradiol if there is sudden partial or complete loss of vision, or sudden onset of proptosis, diplopia, or migraine.
* **Fluid Retention:** Estrogens may cause some degree of fluid retention, and caution is advised in patients with conditions that might be exacerbated by fluid retention, such as cardiac or renal dysfunction.
* **Elevated Blood Pressure:** In a small percentage of individuals, blood pressure increases could be attributed to estrogen therapy.
* **Liver Function:** Estradiol metabolites are primarily excreted through the kidneys and liver. Impaired liver function can affect estradiol metabolism.
Patients should be thoroughly evaluated for personal and family medical history before initiating estradiol and regularly during treatment. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Estradiol is contraindicated in individuals with certain medical conditions due to the risk of exacerbating the condition or causing serious harm. These contraindications include (FDA label, EMA SmPC):
* **Undiagnosed abnormal genital bleeding:** This must be investigated before starting therapy to rule out underlying malignancy.
* **Known, suspected, or history of breast cancer:** Except in very specific circumstances where estrogen is used in the palliative treatment of advanced breast cancer under strict medical supervision.
* **Known or suspected estrogen-dependent neoplasia:** This refers to cancers that are stimulated by estrogen.
* **Active deep vein thrombosis (DVT), pulmonary embolism (PE), or a history of these conditions.**
* **Active arterial thromboembolic disease:** Such as recent stroke or myocardial infarction.
* **Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders.**
* **Known liver dysfunction or disease:** If liver function tests have failed to return to normal.
* **Hypersensitivity to estradiol or any components of the drug product.**
* **Pregnancy:** Estradiol is not indicated for use in pregnancy and may cause fetal harm.
Careful consideration of these contraindications is essential before prescribing estradiol. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
When considering estradiol therapy, it's important to be aware of potential interactions with other medications, as these can affect the efficacy of estradiol or increase the risk of adverse events. While a comprehensive list requires individual consultation, some general categories of interactions include:
* **CYP3A4 Inducers:** Drugs that induce CYP3A4 enzymes (e.g., rifampin, carbamazepine, phenobarbital, St. John's Wort) can increase the metabolism of estradiol, potentially reducing its plasma concentrations and therapeutic effects. This may lead to a recurrence of symptoms (DrugBank).
* **CYP3A4 Inhibitors:** Conversely, drugs that inhibit CYP3A4 (e.g., ketoconazole, erythromycin, ritonavir) can decrease the metabolism of estradiol, potentially increasing its plasma concentrations and leading to an increased incidence of side effects (DrugBank).
* **Thyroid Hormone Replacement Therapy:** Estrogen therapy can increase the requirement for thyroid hormone in patients receiving levothyroxine. Thyroid-stimulating hormone (TSH) levels should be monitored in individuals on both therapies (NIH ODS).
* **Corticosteroids:** Estrogens may decrease the clearance of corticosteroids, leading to an increased risk of corticosteroid-related side effects.
* **Anticoagulants:** Estradiol can alter the effects of oral anticoagulants, potentially leading to a need for adjustment in anticoagulant dosage. The risk of thrombosis is also a consideration (DrugBank).
* **Hepatic C Agents:** Co-administration with certain combination regimens for Hepatitis C (e.g., ombitasvir/paritaprevir/ritonavir with or without dasabuvir) has been shown to cause elevations in ALT levels, particularly in women using ethinyl estradiol-containing products. While direct interaction with estradiol is less extensively studied, caution is warranted (FDA label).
Patients should inform their healthcare provider about all medications, supplements, and herbal products they are currently taking before starting estradiol therapy. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
The typical timing for estradiol administration is highly dependent on the medical condition being treated, the specific formulation, and individual patient needs, as directed by a licensed clinician. It can be administered at any time of day ('any') and generally taken with or without food ('either').
* **Oral tablets:** Often taken once daily. Some regimens may involve cyclical administration (e.g., 25 days on, 5 days off) in conjunction with a progestin.
* **Transdermal patches:** Typically applied twice weekly or once weekly, depending on the patch type and manufacturer's instructions. They provide a continuous and steady release of estradiol.
* **Gels and Sprays:** Usually applied daily to the skin, with the dosage adjusted based on clinical response.
* **Vaginal formulations (creams, tablets, rings):** Applied or inserted according to specific schedules, ranging from daily to weekly or every three months, depending on the product and indication (e.g., for vaginal atrophy). These formulations provide localized effects with minimal systemic absorption.
For menopausal hormone therapy in women with an intact uterus, estradiol is almost always prescribed alongside a progestin to protect the uterine lining from hyperplasia and cancer. The progestin can be taken continuously or cyclically. In women without a uterus (post-hysterectomy), estradiol can be used alone.
The specific regimen, including timing and frequency, is personalized by a healthcare provider after evaluating the patient's symptoms, medical history, and risk factors.
Source for this section: Sources for When should you take Estradiol?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Estradiol?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about Estradiol
Estradiol is a hormone. It is also known as E2 and Estrace. What follows is drawn from peer-reviewed literature indexed on PubMed, FDA label text where a label exists, and NIH reference records.
Estradiol is commonly discussed in the context of supporting bone-joint, menopause, and womens-longevity. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Estradiol, it is typically taken null and its approximate half-life is 15 hours, which influences dosing frequency. Always follow the specific dose your clinician or the product label prescribes.
Estradiol carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
Estradiol is a hormone, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. With a reported plasma half-life near 15 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Estradiol with no sign-up.
Combining a hormone like Estradiol with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against Estradiol: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
With a plasma half-life near 15 hours, once-daily dosing is the usual pattern for Estradiol. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
With a plasma half-life near 15 hours, a single missed dose of Estradiol usually has a smaller effect on overall exposure than an irregular pattern of missed doses does. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Estradiol the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 5991(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/5991
Verify at
Publisher search links for Estradiol. These are places to check the information — they are not citations, so they are not numbered.
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- European Medicines Agency(publisher search, opens in a new tab)European Medicines Agency · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Estradiol?
Plain-text summary, safe to quote verbatim:
Estradiol (E2) is the most potent and abundant naturally occurring estrogen in the human body. It is a steroid hormone primarily responsible for the development and regulation of the female reproductive system and secondary sexual characteristics. Research on Estradiol focuses on bone and joint health, menopause symptoms, and women's healthspan.
Source: DoseRoutine — https://doseroutine.com/library/estradiol
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Estradiol — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/estradiol
What compounds are similar to Estradiol?
Others in the hormone category or studied for the same goals.
Which goals is Estradiol used for?
Other compounds studied for the same benefits as Estradiol.
Continue exploring
See every compound DoseRoutine catalogs for these goals.